C-HCCVCapsida
AAV capsid engineering, targeted genetic medicines, in-house cGMP manufacturing
deliverydeliveringgene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-HCCV
C-HCCVC-HCCVAAV capsid engineering, targeted genetic medicines, in-house cGMP manufacturing
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Capsida Biotherapeutics presents itself as a fully integrated AAV engineering and gene therapy company that believes a high-throughput, biology-driven AAV engineering platform, combined with cargo development and state-of-the-art manufacturing, can generate targeted and potentially best-in-class gene therapies for a broad range of debilitating and life-threatening genetic disorders.
SourceCapsida Biotherapeutics presents the view that novel AAV engineering, integrated clinical development, and strong discovery, preclinical, and manufacturing capabilities can unlock the broader potential of gene therapy and enable the next generation of treatments.
SourceCapsida states that existing gene therapy approaches can achieve dramatic efficacy in rare diseases but are limited by imprecise targeting. The company’s stated belief is that selectively transducing specific cells and tissues is critical to creating safer, more effective gene therapies for debilitating and life-threatening genetic disorders in both CNS and non-CNS indications.
Source